0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Exhibition > Bio-insider virtual event - Diagnostic Landscape for COVID-19
  1. Bio-insider virtual event - Diagnostic Landscape for COVID-19

    1. Thursday, June 18, 2020,10:00am-4:30pm EST
    2. Online
    3. Teng Peng, PhD, Technical Application Manager, ACROBiosystems (10:55am)
    ACRO Talk:The Critical Role of Antigens in COVID-19 Serological Test Development. Join Us!
  2. We are sponsoring and presenting at Bio-insider virtual event - Diagnostic Landscape for COVID-19


    Time: Thursday, June 18, 2020,10:00am-4:30pm EST    


    10:00 AM

    Organizer’s Opening Remarks


    Emily Le, PhD, Founder & CEO, Bioinsider


    10:05

    Program Chairperson’s Opening Remarks


    Karl V. Voelkerding, MD, Professor, Pathology, University of Utah; Medical Director for Genomics and Bioinformatics, ARUP Laboratories


    10:10

    Comparing Diagnostic Methods for COVID-19: Practical and Statistical Considerations


    Timothy J. O' Leary, MD, PhD, Adjunct Professor, Pathology, University of Maryland School of Medicine; Former Chief Research and Development Officer, Veterans Affairs


    Performance comparisons among diagnostic tests require attention to timing, ease, and appropriateness of use, sensitivity, and specificity. The talk will address points to consider when evaluating literature making such comparisons, as well as practical and statistical considerations that should inform diagnostic device comparisons.


    10:35

    Multiplatform Comparisons of Molecular Tests for COVID-19: Predicting Differences in Case Detection


    David Hillyard, MD, Medical Director, Molecular Infectious Diseases; Professor, University of Utah School of Medicine


    This talk will summarize current methods used to determine the analytic sensitivity of EUA approved COVID-19 tests and approaches to determine the impact of test sensitivity on case detection.


    10:55

    The Critical Role of Antigens in COVID-19 Serological Test Development


    Teng Peng, PhD, Technical Application Manager, ACROBiosystems


    High-quality recombinant SARS-CoV-2 antigens play an essential role for the development of antibody test kits. The selection of construct and expression host cell are key determinants in producing antigen proteins with high bioactivity and batch-to-batch consistency. Optimization of constructs and screening of expression host cell can lead to suitable antigens for serological test development.


    11:05

    Speed Networking


    11:25

    Session Break


    11:35

    Development, Implementation, and Regulation of Diagnostic Methods at the State Level – New York Perspective


    Kirsten St. George, PhD, Director, Virology Laboratory; Chief, Viral Diseases, Wadsworth Center; Clinical Professor, School of Public Health, Biomedical Sciences, SUNY 


    From the earliest days of diagnostic testing and initial emergency use authorizations, through current day challenges of large-scale screening of health care personnel and patients, the COVID-19 pandemic has presented unprecedented challenges to all laboratories. This presentation will provide an overview of experiences at the New York state public health laboratory including diagnostic, regulatory, and research response efforts.  


    12:00 PM

    Development and Scaling of the LabCorp COVID-19 RT-PCR Test


    Brian Krueger, Associate Vice President, Technical Director, R&D at LabCorp


    LabCorp was the first commercial diagnostics company to receive emergency use authorization for COVID-19 RT-PCR testing and at-home collection of COVID-19 samples. Development began in late January and culminated with the at-home collection approval on April 20, 2020. LabCorp has since scaled its PCR testing operation to over 100,000 samples per day with a turnaround time of 1-2 days.


    12:25

    Speed Networking


    12:45

    Session Break


    1:30

    The Rapidly Evolving Role of Antibody Testing for SARS CoV-2


    Co-presenter: Patricia Slev, D(ABCC), Section Chief Immunology Division, Medical Director Core Immunology; Medical Director Microbial Immunology, Medical Director Serologic Hepatitis and Retrovirus Laboratory; Associate Professor, Pathology, University of Utah


    Co-presenter: Elitza Theel, PhD, Associate Professor, Laboratory Medicine, and Pathology, Mayo Clinics


    Serology testing for SARS CoV-2 is now available on a number of platforms and more are receiving approval each day. This presentation will provide an overview of the current assays, including appropriate use of the different methodologies for antibody testing, clinical utility, and result interpretation.


    What We Know About Serology Testing - An Interview with Dr. Patricia Slev


    1:55

    Interpretation of COVID-19 Diagnostic Test Results: A Clinician' s Perspective


    Ralph Rogers, MD, Assistant Professor of Medicine, Clinician Educator, Infectious Diseases, Warren Alpert Medical School of Brown University


    The rapidly expanding number of diverse SARS-CoV-2 molecular and serologic tests now available to clinician’s paired with the disparate performance characteristics of various assays may lead to challenges when interpreting test results. This case-based presentation will explore the limitations of currently available diagnostics in various clinical scenarios, and will highlight important factors to consider when ordering and interpreting these tests.


    2:20  Session Break


    2:30

    Home Collection of Nasal Specimens – Lowering the Barrier to SARS-CoV-2 Testing and Expanding Access to Care


    Karen A. Heichman, PhD, Senior Program Officer, Diagnostic Development, Innovative Technology Solutions, Global Health Division, Bill & Melinda Gates Foundation


    Diagnostic testing for SARS-CoV-2 remains a challenge today, even after several weeks and with the emergence of a number of innovations. In the first weeks of the epidemic in the US, it became clear that even specimen collection was severely limited by shortages in NP swabs, viral transport media, medical personnel to collect specimens and PPE to prevent the exposure of healthcare works while collecting specimens. The knowledge that a simple nasal swab made of spun polyester, which may be manufactured inexpensively and at high capacity, together with the finding that a swab may be stably stored and transported to the lab for testing in a dry tube, without cold chain, has lowered the barrier to specimen collection and is enabling for self-collection in the home or workplace. We believe that a pre-positioned home collection kit, comprised of a polyester nasal swab, a simple tube and collection instructions, could dramatically broaden the access to SARS-CoV-2 testing in both the developed world as well as in low and middle income countries.


    2:45

    Closing Panel Discussion: Considerations for All Tests and How to Properly Handle the Pandemic with the Current Testing Capacity


    Moderator: Karl V. Voelkerding, MD, Professor, Pathology, University of Utah; Medical Director for Genomics and Bioinformatics, ARUP Laboratories


    Panelists: Karen A. Heichman, PhD, Senior Program Officer, Diagnostic Development, Innovative Technology Solutions, Global Health Division, Bill & Melinda Gates Foundation


    Yuan-Po Tu, DVM, MD, Urgent Care Physician, Medical Director, Flu Services, Anticoagulation, Epic Provider Efficiency, The Everett Clinic-Part of Optum


    Ralph Rogers, MD, Assistant Professor of Medicine, Clinician Educator, Infectious Diseases, Warren Alpert Medical School of Brown University


    Brian Krueger, Associate Vice President, Technical Director, R&D at LabCorp


    Timothy J. O’Leary, MD, PhD, Adjunct Professor, Pathology, University of Maryland School of Medicine; Former Chief Research and Development Officer, Veterans Affairs


    3:15

    End of Main Event and Transition to Breakout Discussion


    3:30 - 4:30

    Breakout Discussion


    Join our 1-hour breakout discussions for face time with our speakers and your peers. These are informal, moderated discussions featuring brainstorming and interactive problem solving—allowing participants from diverse backgrounds to exchange ideas and experiences, and develop future collaborations around a focused topic. In order to ensure effective discussion, breakout discussions will have a maximum of 10-15 attendees per room and are on a first-come, first-served basis.


    * Separate registration required and space is limited. To register, click here.


    Breakout Room 1: Translational Diagnostic Pipelines: Pre-clinical and Clinical Best Practices


    Moderator: John Sninsky, Consultant, Translational Sciences


    Balancing diagnostic, therapeutic and vaccine development

    Best practices and key regulatory guidance for translational diagnostics

    Comparative diagnostic performance metrics


    Breakout Room 2: Biomarkers to Predict Severe COVID-19


    Moderator: Sam Ali, PhD, Strategic Partnerships and Ventures at Denka Corporation


    Why do some patients exhibit severe disease manifestation?

    Discovering predictive severity biomarkers

    Strategies for applying mass screening for predicting severe COVID-19 patient


    Breakout Room 3: What We Know About Serology Testing


    Moderator: Patricia Slev, D(ABCC), Section Chief Immunology Division, Medical Director Core Immunology; Medical Director Microbial Immunology, Medical Director Serologic Hepatitis and Retrovirus Laboratory; Associate Professor, Pathology, University of Utah


    Best practices for serology testing

    Serology testing applications

    The science behind antibody testing


    Breakout Room 4: Ongoing Challenges with COVID-19 Diagnostics


    Moderator: Kirsten St. George, PhD, Director, Virology Laboratory; Chief, Viral Diseases, Wadsworth Center; Clinical Professor, School of Public Health, Biomedical Sciences, SUNY


    What is the situation with antigen testing?

    Do we still need more molecular assays or platforms?

    Is there any role for culture and does it really need BSL-3?

    The elephant in the room – the authorization of tests


    Breakout Room 5: Rapid Testing


    Moderator: Timothy J. O’Leary, MD, PhD, Adjunct Professor, Pathology, University of Maryland

    School of Medicine; Former Chief Research and Development Officer, Veterans Affairs


    How do we most effectively use rapid diagnostic tests, such as ID NOW and Xpert/Xpress, in the emergency room setting?

    Is there a role for rapid diagnostic testing in surveillance of Covid19-facing healthcare personnel?

    What, if any, is the best way to use lateral flow serologic testing in dealing with the Covid-19 pandemic.


    Breakout Room 6: Clinical Considerations When Testing for SARS-CoV-2


    Moderator: Yuan-Po Tu, DVM, MD, Urgent Care Physician, Medical Director, Flu Services, Anticoagulation, Epic Provider Efficiency, The Everett Clinic-Part of Optum 


    Timing and selection of SARS-CoV-2 tests

    Optimizing specimen collection for diagnostic testing

    Alternative options when facing swab and transport media shortages


    4:30

    End of Diagnostic Landscape for COVID-19

    1592205927640636.jpg

New & Hot Products


This web search service is supported by Google Inc.

totop